There is a need for large-scale observational studies or head-to-head randomized trials that evaluate whether liraglutide, semaglutide, dulaglutide, and newer dual agonists such as tirzepatide offer different cancer risks or benefits due to their structural differences
D.C reports serving or having served as a consultant for Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometric, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, GSK and Novo-Nordisk
Choose the Injection Site The most common sub-Q injection sites are: The abdomen (avoiding the 2-inch area around your belly button) The outer thigh The back of the upper arm Use a rotation system for injection sites to avoid irritation or tissue damage
PMC 6802138